Company Update | Dr Chris Burns shares a brief overview of recent activities, including the Company’s new OTC listing in the US and upcoming clinical and manufacturing milestones for its best-in-class FAK inhibitor in pancreatic cancer. Take a look:

Amplia Therapeutics U.S. has begun trading on the U.S. OTCQB Venture Market under the code INNMF effective 29 October. Read the ASX release: https://t.co/cvueR8Ep9b $ATX #Amplia #pancreaticcancer #clinicaltrials #OTCQB #innovation #biotech

Amplia has today released its Quarterly Activities and Cash Flow Reports for the period ending 30 September 2025. Read the ASX release: https://t.co/VgFBgXN9Ow $ATX #Amplia #innovation #biotech #ASX #clinicaltrial #pancreaticcancer

$ATX #Amplia #innovation #clinicaltrials #pancreaticcancer #biotech #R&D #research

Amplia has received A$3.77 million under the Australian Government’s Research and Development Tax Incentive program for the financial year ended 31 March 2025. Read the ASX release: https://t.co/nnrAHMI01N

NOW LIVE | We’re pleased to launch the new website for our AMPLICITY clinical trial - a study evaluating narmafotinib in combination with FOLFIRINOX for patients with metastatic pancreatic cancer. Take a look: https://t.co/JdaaYNRS6S $ATX #Amplia #clinicaltrials #pancreaticcancer

Last week, our team came together at our new office to celebrate #Frocktober, raising $1,736 to support ovarian cancer research — a cause that closely aligns with our mission to advance new treatments for hard-to-treat cancers. $ATX #Amplia #OvarianCancer #CancerResearch

#Amplia is expanding its U.S. presence to boost investor awareness & engagement. As its Phase 1b/2a AMPLICITY trial continues in the U.S. and Australia, Amplia has launched a U.S. capital markets campaign and is pursuing an OTCQB uplisting. https://t.co/t0A2woWlRF #clinicaltrials

Amplia CEO Dr Chris Burns and COO Dr Rhiannon Jones met with investors and analysts in Melbourne to talk about Amplia’s growing clinical momentum. Thanks to those who attended. View the presentation here: https://t.co/bz1D2UKIZ1 $ATX #Amplia #pancreaticcancer #clinicaltrials

New Data | Amplia’s ongoing ACCENT clinical trial in advanced pancreatic cancer has recorded an additional confirmed partial response and one unconfirmed partial response. Read the ASX release: https://t.co/jQNzp2wrjo $ATX #Amplia #clinicaltrial #pancreaticcancer #innovation

$ATX | #Amplia CEO Dr Chris Burns recently joined Michael Frazis for an in-depth interview on our FAK inhibitor, narmafotinib. The interview covers its potential to enhance chemotherapy, ACCENT trial progress & the Company’s midterm strategy. Take a look:

$ATX #Amplia #intellectualproperty

Amplia has received notification from the US Patent and Trademark Office (USPTO) that a key patent protecting narmafotinib has been allowed in the US. Formal ‘Notification of Grant’ is expected in the coming months. Read the ASX release:  https://t.co/6lXfR264AG

$ATX #Amplia #OvarianCancer #ClinicalTrials #GynecologicalCancerAwarenessMonth

September is Gynecological Cancer Awareness Month, shining a light on ovarian cancer, which claims over 1,000 Australian lives each year. Preclinical research suggests Amplia’s narmafotinib may have potential in chemotherapy-resistant ovarian cancer - a focus for future studies.

$ATX VIDEO | #Amplia CEO Dr Chris Burns & COO Dr Rhiannon Jones share Company highlights, including a $27.5M capital raise, positive ACCENT study data, and the launch of the Amplicity trial, with Australian sites open and U.S. sites to follow.

$ATX | Yesterday in Sydney, #Amplia CEO Chris Burns & COO Rhiannon Jones attended an investor lunch, sharing emerging data & upcoming milestones for narmafotinib #pancreaticcancer trials in Australia, Korea & the US. View the presentation: https://t.co/txB2qWWHB8

$ATX | #Amplia has enrolled and has begun dosing the first patient in the Company's new pancreatic cancer trial, exploring narmafotinib in combination with FOLFIRINOX in newly diagnosed advanced #pancreaticcancer patients. Read the ASX release: https://t.co/zW6UQPUMuk

#Amplia has announced that the United States Adopted Names (USAN) Council has approved the name narmafotinib as the nonproprietary drug name for Amplia Therapeutics' lead FAK inhibitor. Read the ASX release: https://t.co/O1H7LDAuBv $ATX #clinicaltrial #pancreaticcancer

#Amplia has announced the opening of two Australian clinical trial sites for the Company’s new study investigating narmafotinib with FOLFIRINOX in newly diagnosed metastatic #pancreatic #cancer patients. Read the ASX release: https://t.co/Xe3cSpQhwb $ATX #pharma #clinicaltrial